<DOC>
	<DOCNO>NCT00196755</DOCNO>
	<brief_summary>The purpose study demonstrate sevelamer hydrochloride non-inferior calcium acetate treatment hyperphosphataemia patient receive peritoneal dialysis .</brief_summary>
	<brief_title>Study Safety Efficacy RenagelÂ® Compared With Calcium Acetate Patients With Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>Willing able sign inform consent form . Men woman age 18 year age older . A diagnosis Chronic Kidney Disease ( CKD ) receive peritoneal dialysis ( Continuous cyclical peritoneal dialysis ( CAPD ) , Automated peritoneal dialysis ( APD ) Continuous cyclical peritoneal dialysis ( CCPD ) 8 week longer . In opinion investigator , expect receive peritoneal dialysis duration study . Will serum phosphorus level &gt; 1.76 mmol/L ( 5.50 mg/dL ) 2 week washout usual phosphate binder . Will serum calcium measurement adjust albumin within range ( 2.102.60 mmol/L ( 8.4010.40 mg/dL ) follow 2 week washout usual phosphate binder . Willing maintain prescribe sevelamer calcium acetate duration study . Considered compliant phosphate binder dialysis . On stable dos medication treat hyperparathyroidism ( Vitamin D analogues calcimimetic agent ) month prior screen . Willing discontinue use antacid contain calcium , aluminium magnesium screen visit duration study ( unless take evening calcium supplement prescribe investigator per protocol ) . Willing avoid intentional change diet fast dieting . If female childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study , include barrier method , hormone , Intrauterine device ( IUDs ) . Have level understanding willingness cooperate visit procedure describe study personnel . Patients history peritonitis last 30 day &gt; 2 episode last 12 month Patient active dysphagia , swallow disorder , bowel obstruction , severe gastrointestinal motility disorder . Patients opinion investigator poorly control diabetes mellitus , poorly control hypertension , active vasculitis , Human Immunodeficiency Virus ( HIV ) infection , clinically significant , unstable medical condition . Patients evidence active malignancy except basal cell carcinoma skin . A history malignancy exclusion . Current use antiarrhythmic medication quinidine , procainamide , tocainide , amiodarone control arrhythmia . Current use seizure medication phenytoin , phenobarbital , valproate , carbamazepine control seizure disorder . Active ethanol drug abuse , exclude tobacco use . If female , pregnant , plan become pregnant next 6 month breastfeed . Patients know hypersensitivity sevelamer constituent either study drug . Patients participate study investigational drug/device 30 day precede start screen period . Patients condition , opinion investigator prohibit patient 's participation study . Patient unable comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>